Role of GLP-1 Agonists in Neurodegenerative Diseases

GLP-1 agonists have garnered attention not only for their applications in diabetes management and weight loss but also for their potential neuroprotective properties in neurodegenerative diseases. Preliminary studies suggested that these agents, particularly exenatide, could modify disease progression in conditions like Parkinson's and Alzheimer's disease. Recent trials, however, have delivered mixed results, with a phase 3 trial on exenatide failing to demonstrate significant differences compared to placebo in Parkinson’s patients. The findings highlight the complexity of translating preclinical optimism into clinical efficacy, emphasizing the need for further exploration of these medications.